Aster Capital Management DIFC Ltd Buys New Shares in Pfizer Inc. $PFE

Aster Capital Management DIFC Ltd bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, Holdings Channel.com reports. The fund bought 33,445 shares of the biopharmaceutical company’s stock, valued at approximately $833,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. United Bank increased its stake in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. increased its stake in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC increased its stake in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s CEO said the company could eventually return to high-single-digit growth, suggesting the business may be stronger than investors expect and improving the long-term growth narrative. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Positive Sentiment: Pfizer’s obesity pipeline got a boost after Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and support for moving into Phase 3, which could add a new growth driver. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: RBC Capital upgraded Pfizer, reinforcing the view that the stock’s dividend and valuation may be attractive relative to peers. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Neutral Sentiment: Pfizer is drawing heavy investor search interest and additional research coverage, indicating rising attention but not necessarily a direct fundamental catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Analyst commentary continues to focus on Pfizer’s discounted valuation, fading COVID revenues, and looming patent expirations, leaving the stock’s longer-term rerating story still uncertain. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?
• Neutral Sentiment: Pfizer was also included in a “Top Research Reports” roundup, which adds visibility but does not appear to change the investment thesis on its own. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Ongoing concerns about patent cliffs and declining legacy COVID-related sales continue to cap enthusiasm for Pfizer’s near-term earnings growth. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Stock Performance

Shares of NYSE:PFE opened at $26.01 on Tuesday. The firm has a market capitalization of $148.24 billion, a PE ratio of 19.86 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business has a 50-day moving average of $26.38 and a two-hundred day moving average of $26.33. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is presently 131.30%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. Barclays assumed coverage on Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company. Finally, HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.